Insight

Gustavo Viani: SBRT should be considered a treatment option in various HCC stages

Gustavo Viani/onconews.com.br

Nov 8, 2024, 17:16

Gustavo Viani: SBRT should be considered a treatment option in various HCC stages

Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology, shared a recent article by Satoshi Komiyama on LinkedIn:

“SBRT should be considered a treatment option in various HCC stages in cancer treatment Guidelines.

Objective-

To evaluate the efficacy of Stereotactic Body Radiation Therapy (SBRT) Transcatheter Arterial.

Chemoembolization(TACE) for treating hepatocellular carcinoma(HCC).

Methods-
•Meta-Analysis: data from randomized controlled trials and retrospective studies using propensity score analysis.
•Outcomes: Hazard Ratios (HRs) for Overall Survival (OS) and Local Control (LC).

Outcomes-
• Comparable OS: SBRT and TACE Overall Survival (HR: 0.83; 95% CI: 0.52–1.34; p = 0.44).
• Improved LC: SBRT showed Local Control over TACE (HR: 0.25; 95% CI: 0.09–0.67; p = 0.006).
• Safety Profile: No significant difference in grade 3+ toxicities between SBRT TACE, though liver toxicity was common in both.”

Gustavo Viani: SBRT should be considered a treatment option in various HCC stages

Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis.

Authors: Satoshi Komiyama, et al.

Gustavo Viani: SBRT should be considered a treatment option in various HCC stages

Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.